Frequency of serum tumour marker monitoring in patients with non-seminomatous germ cell tumours. by Seckl, M. J. et al.
Br. J. Cancer (1990), 61, 916-918
C) Macmillan
Frequency of serum tumour marker monitoring in patients with
non-seminomatous germ cell tumours
M.J. Seckl, G.J.S. Rustin & K.D. Bagshawe
Department ofMedical Oncology, Cancer Research Campaign Laboratories, Charing Cross Hospital, Fulham Palace Road,
London W6 8RF, UK.
Summary In patients relapsing on surveillance following orchidectomy for stage I non-seminomatous germ
cell tumours, it is essential that treatment is initiated before they develop advanced disease with a poor
prognosis. Patients who start chemotherapy with levels of human chorionic gonadotrophin (HCG) > 1,000
i.u. 1- and/or alpha-fetoprotein (AFP) level > 500 ku 1 have been shown to have a worse prognosis than
patients with lower marker levels. We studied 64 patients between 1968 and 1987 with rising serial tumour
markers. The potential time in which markers could rise to poor prognostic levels was calculated assuming an
exponential rate of increase. Adverse levels were predicted in one patient (1.6%) within 7 days, in two patients
(3.1%) within 14 days, in eight patients (12.5%) within 4 weeks and in 16 patients (25%) within 6 weeks. This
suggests that, initially, weekly marker estimations should be performed on stage I surveillance patients. The
extra cost to a specialist follow-up laboratory of weekly as opposed to the usual monthly marker measure-
ments will be less than £33,600 for every 400 patients on surveillance. One extra patient is likely to be cured
for this sum.
Human chorionic gonadotrophin (HCG) and/or alpha-feto-
protein (AFP) are elevated in the serum of about 80% of
patients with non-seminomatous germ cell tumours (NSGCT)
(Newlands, et al., 1976; Norgaard-Pederson et al., 1984;
Javadpour, 1979). The prognostic value of tumour markers
in patients wtih germ cell tumours was first demonstrated in
1980 (Germa-Luck et al., 1980). An initial HCG >50,000
i.u. -' and/or an AFP >500 ku 1` were shown to be the
most important indicators of failure to achieve complete
remission following chemotherapy. Later studies have
confirmed the prognostic significance of HCG and AFP
values with the largest studies using HCG levels of
> 1,000 i.u. I` or >5,000 i.u. 1' as indicators of poor sur-
vival (MRC Working Party on Testicular Tumours, 1985;
Stoter et al., 1987; Bosl et al., 1983). Tumour markers are
measured regularly in patients on surveillance for stage 1
disease, on chemotherapy, and on follow up after therapy.
The frequency of these measurements should be determined
by how quickly the HCG or AFP could reach levels
associated with a worse prognosis before intervention. The
potential doubling time of these markers in patients with
NSGCT has not previously been reported. We therefore
analysed the records of such patients treated at the Charing
Cross Hospital to determine the shortest potential doubling
time of HCG and AFP. This enables us to advise on the
optimal frequency of marker estimation.
Patients and methods
Three groups of patients were studied. Patients without a
serial rise in markers, who were non-marker producers or in
whom data was incomplete were excluded from evaluation
and are given as denominators below. Group 1: those treated
before the introduction of cisplatin; 35 of 80 patients treated
between 1968 and 1976. Group 2: those who progressed on
or relapsed after cisplatin-based combination chemotherapy;
19 of 37 treated between 1977 and 1987. Group 3: Those
with stage 1 disease who subsequently required treatment; 10
of 19 followed up between 1979 and 1987. HCG and AFP
were measured with specific radioimmunoassays developed in
this department.
The maximum rate of marker rise was measured for each
patient and converted into the number of marker doublings/
week. Example: Patient A.D. on 8 August 1986 had an
AFP = 24 (x) and on 15 September 1986 had an AFP = 228
(y). Using the equation:
log1o (y/x)
loglo 2
implies 3.25 marker doublings in 38 days assuming an ex-
ponential rate of increase and (7/38) x 3.25 = 0.6 doublings
per week.
An HCG >1,OOOi.u.1-' and an AFP >500kul-' were
used to indicate poor prognosis. An AFP <10 ku 1- is
normal and therefore 5.6438 doublings gives the cut-off value
for poor prognosis of 500. Similarly an HCG <5 i.u. 1' is
normal and thus to exceed the poor prognosis value of 1,000
requires 7.6438 doublings using the above equation.
Results
Table I shows the mean, median and range of marker doub-
lings per week for each of the three groups studied. Although
the range of marker doublings is wide, most patients have a
relatively slow doubling time of between 0.2 and 1 doublings
per week. The cisplatin failures and stage 1 relapse groups
have similar mean and median values which are smaller than
the pre cisplatin patients.
Patients in the latter group could potentially achieve AFP
and HCG levels in the poor prognosis range within a week.
By contrast cisplatin failure patients (group 2) required 48
days for AFP and 40 days for HCG to reach poor prognosis
values. Stage 1 patients on surveillance could potentially
exceed a poor prognosis AFP value in 70 days and HCG in
45 days.
Figure 1 shows the percentage of patients whose markers
could potentially reach the poor prognosis level within 1-6
weeks. All patients on surveillance for stage 1 disease re-
ceived therapy before poor prognosis marker values were
attained, because we performed weekly marker estimations.
There were five patients who relapsed off therapy after treat-
ment with cisplatin whose levels rose above the poor prog-
nostic value before restarting treatment. The actual numbers
ofmarker doublings observed (from elevated plateau levels in
two cases) were 1.5, 1.6, 2.3, 6.9 and 9.2; the numbers of
doublings per week were 0.33, 0.33, 0.9, 0.8 and 0.45 respec-
tively. In the pre-cisplatin era the patients were receiving
chemotherapy which would be expected to decrease the rate
of marker rise. However, there were still two patients in this
group who had a total of >8 HCG doublings with a rate of
0.53 and 2.07 doublings per week.
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Table I Marker doublings per week
Patient group No. Mean Median Range
Pre-cisplatin
(group 1)
HCG producers 34 1.40 0.97 0.24-6.9
AFP producersa 1 - - 7.56
Cisplatin failures
(group 2)
HCG producers 11 0.81 0.71 0.38-1.4
AFP producers 8 0.52 0.6 0.33-0.86
Stage I
(group 3)
HCG producers" 6 0.56 0.47 0.22-1.26
AFP producersb 5 0.48 0.53 0.29-0.60
8AFP assays only became fully available in 1975 and thus the real
numberofmixed secretory tumours ismuchhigherthanpresented here.
bInclude mixed marker producers.
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Figure 1 The percentage of patients whose markers could poten-
tially reach the poor prognosis level (HCG> 1,000 i.u. 1` and/or
AFP>500ku 1-') within 1-6 weeks.
Discussion
Serial measurements of AFP and HCG are of great value in
assessing response to chemotherapy, detecting relapse and
enabling therapy to commence before patients with NSGCT
are assigned to a poor prognosis (Newlands et al., 1976;
Norgaard-Pedersen et al., 1984; Javadpour, 1979; Germa-
Luck et al., 1980; MRC Working Party on Testicular Tu-
mours, 1985; Stoter et al., 1987; Bosl et al., 1983; Crawford
et al., 1988). However, there is no general agreement between
centres concerning the frequency of marker estimation during
treatment and follow-up. Our results suggest that if only
monthly marker estimations are performed, 16 of 64 (25%)
patients could have levels within the poor prognostic range
by the time they start chemotherapy at 6 weeks. The addi-
tional 2 week delay occurs because most centers do not start
treatment on the basis of one raised result and therefore
require repeat tests. Even weekly marker estimations could
result in three of 64 (4.7%) patients having poor prognosis
marker levels within 3 weeks. At least two points need to be
considered when enterpreting the data. Firstly our calculation
ofpotential marker doubling time is based on the assumption
of an expontial rate of marker rise. In fact many patients had
marker rises which were initially rapid, but often briefly
plateaued within a good prognosis range. This provides a
potential 'breathing space' to institute therapy, and makes us
confident in suggesting weekly rather than more frequent
marker estimations. The observation of one patient having
9.2 doublings in 31 days suggests that the potential doubling
time that we have calculated can indeed occur.
Secondly the worst pre-cisplatin patients took only 5-8
days to enter a poor prognosis category whereas the worst
cisplatin failure or stage 1 follow-up patients needed 40-70
days. This difference could be attributed to the lower res-
ponse rates with non-cisplatin therapy. Perhaps the most
likely explanation is the smaller number ofpatients studied in
both the stage 1 follow-ups and the cisplatin failure groups,
i.e. if enough stage 1 follow-ups had been studied some may
have had marker rises as fast as seen in the pre-cisplatin era.
We therefore still regard weekly marker estimation as
sufficient for stage 1 follow-up patients, at least during the
first 6 months, since most relapses occur within this time
(Crawford et al., 1988; Freedman et al., 1987). For post-
treatment patients, weekly marker measurements are
similarly appropriate, although the best chance of cure
occurs with the first treatment cycle and not at relapse.
Corroborative evidence that our recommendation of weekly
marker levels is correct comes from a recent MRC study
(MRC Working Party on Testicular Tumours, 1985). Of 259
patients with stage 1 disease on surveillance, three died. One
of these had an HCG level of over 30,000 i.u. 1' on relapse,
but only had tumour marker levels performed once every 4
weeks (W.G. Jones, personal communication). A summary of
our recommendations for frequency of tumour marker
measurements in NSGCT is provided in Table II.
Table II Recommended frequency of marker estimation
Patient group
Stage 1 follow-ups and post-treatment Weekly for 26 weeks
Monthly for 1.5 years
2 monthly for 3rd year
3 monthly for 4th year
Then 6 monthly
During treatment Weeklya
aNot based on data from this paper.
Clearly, performing more frequent marker tests incurs ex-
tra cost. Using the automated follow-up service at the Char-
ing Cross Hospital, the overall costs of an HCG and AFP
assay are £6. The cost of marker analysis for 400 stage 1
surveillance patients over 2 years would be £57,600 if per-
formed monthly and £91,200 if performed weekly for 26
weeks, then monthly for 1.5 years; a difference of £33,600.
Approximately 100 of these 400 patients would be expected
to relapse (Crawford et al., 1988; Freedman et al., 1987).
Eighty of these patients would be marker producers of whom
as many as 12.5% could develop poor prognostic markers
within 4 weeks (Figure 1). There is at least a 10% survival
difference between patients with good and poor prognosis
marker values (Germa-Luck et al., 1980; MRC Working
Party on Testicular Tumours, 1985; Stoter et al., 1987; Bosl
et al., 1983; Newlands et al., 1986). Initial weekly marker
estimations would therefore be expected to result in at least
an extra 1:400 patients becoming long-term survivers for
only an extra £33,600. This, in our view, is very cost-effective.
The inconvenience of more frequent blood tests can be
reduced by using an automated follow up scheme such as
that developed at Charing Cross Hospital (Rustin, 1986).
Returnable boxes are sent to the patient's home address with
a request for them to attend the nearest pathology depart-
ment by the specified date, and serum is sent in the box to
the assay laboratory.
It is hoped that better marker follow up will reduce the
likelihood of patients on surveillance for NSGCT falling into
a poor prognosis category and enable less toxic therapy to be
utilised at an earlier date.918 M.J. SECKL et al.
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